Jennifer Swainson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer Swainson has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Atul Khullar
Department of Psychiatry, University of Alberta, 3rd floor Cabrini Center c/o Misericordia Hospital 16940 87 Ave NW, Edmonton, AB T5R 4H5, Canada
13 shared publications- Gilmar Gutierrez
Department of Psychiatry, University of Alberta, 3rd floor Cabrini Center c/o Misericordia Hospital 16940 87 Ave NW, Edmonton, AB T5R 4H5, Canada
7 shared publications - Gustavo Vazquez
Department of Psychiatry Queen's University Kingston Ontario Canada
5 shared publications Carson Chrenek
Department of Psychiatry, University of Alberta, 3rd floor Cabrini Center c/o Misericordia Hospital 16940 87 Ave NW, Edmonton, AB T5R 4H5, Canada
4 shared publications- Lisa Burback
Department of Psychiatry, University of Alberta, Edmonton, AB, Canada
4 shared publications - Olga Winkler
Department of Psychiatry, University of Alberta, Edmonton, AB, Canada
4 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in npj Mental Health Research
- Vol. 5 (1) , 43
A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with Psychotherapy (KCP/ES-KCP), where an altered state is not necessary for psychotherapy, or Ketamine/Esketamine Assisted Psychotherapy (KAP/ES-KAP), where an altered state and/or integration of the experience is central to the psychotherapy. The 47 included 23/47(49%) KAP, 1/47 (2%) ES-KAP, 7/47 (15%) KCP, 3/47 (6%) ES-KCP, 8/47 (17%) dual KAP/KCP and 1/47 (2%) dual ES-KAP/ES-KCP. Four studies could not be categorized. Separation into these categories was useful to more clearly report current state of the literature. Though previous reviews have suggested KAP is of benefit for depression, KAP studies were limited by lack of RCTs, lack of comparison groups without psychotherapy, and a large number of individual case reports. To date, fewer studies, but higher quality data support a KCP model, with 3 studies suggesting benefit to combining ketamine with cognitive behavioral therapy (CBT). Further, high quality research including accurate reporting and description of psychotherapy model is required.
- 27 July 2026
- Published by Springer Nature in npj Mental Health Research
- Vol. 5 (1) , 43
Open AccessA scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with Psychotherapy (KCP/ES-KCP), where an altered state is not necessary for psychotherapy, or Ketamine/Esketamine Assisted Psychotherapy (KAP/ES-KAP), where an altered state and/or integration of the experience is central to the psychotherapy. The 47 included 23/47(49%) KAP, 1/47 (2%) ES-KAP, 7/47 (15%) KCP, 3/47 (6%) ES-KCP, 8/47 (17%) dual KAP/KCP and 1/47 (2%) dual ES-KAP/ES-KCP. Four studies could not be categorized. Separation into these categories was useful to more clearly report current state of the literature. Though previous reviews have suggested KAP is of benefit for depression, KAP studies were limited by lack of RCTs, lack of comparison groups without psychotherapy, and a large number of individual case reports. To date, fewer studies, but higher quality data support a KCP model, with 3 studies suggesting benefit to combining ketamine with cognitive behavioral therapy (CBT). Further, high quality research including accurate reporting and description of psychotherapy model is required.
- Open Access
- 12 May 2026
- Published by Elsevier in Psychiatry Research
- Vol. 363, 117221
Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis
- 12 May 2026
- Published by Elsevier in Psychiatry Research
- Vol. 363, 117221
Open AccessKetamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis
- Open Access
- 28 October 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (2) , 83-88
Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models
There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid proliferation of clinics/programs offering a variety of ketamine based treatments. A quick glance at the existing evidence, however, reveals a confusing scenario for patients, healthcare providers, and regulators. Overall, there are no standard definitions of what constitutes a psychotherapeutic intervention within a psychedelic-based or a ketamine-based treatment. More specifically, studies have not always distinguished between using a well-known, manualized psychotherapy, providing psychoeducation and psychological support, or providing a therapy specifically to integrate the drug experience in psychedelic trials. Also, it is difficult to determine the role of the psychedelic agent as a stand-alone treatment, and the relative importance (if any) of the psychedelic experience for the desired therapeutic effect. In this perspective, we discuss the evolving landscape of psychedelic-based and ketamine-based treatments, highlighting different therapeutic models, their methodologies, and the need for clearer definitions and rigorous clinical trials. The document proposes three new definitions to improve clarity in evaluating the effects of these agents and the role of psychotherapies. We suggest language that will distinguish: (1) when the drug is used for its pharmacologic effects as a stand-alone treatment, without requiring the psychedelic experience or combined psychotherapy; (2) when the treatment requires the acute psychological effects of the drug to assist psychotherapy and (3) When ketamine or a psychedelic agent is used in combination with a structured, manualized psychotherapy that could be implemented even in the absence of these agents. We hope that this new terminology and definitions will help distinguish the various therapeutic roles of these agents (as stand-alone treatments or in combination with psychotherapies), and facilitate study designs, regulatory pathways, and more informed patient care. Plain Language Summary Title: Ketamine, Psychedelics, and Psychotherapy: Understanding treatment models to better inform practice
- 28 October 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (2) , 83-88
Open AccessKetamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models
There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid proliferation of clinics/programs offering a variety of ketamine based treatments. A quick glance at the existing evidence, however, reveals a confusing scenario for patients, healthcare providers, and regulators. Overall, there are no standard definitions of what constitutes a psychotherapeutic intervention within a psychedelic-based or a ketamine-based treatment. More specifically, studies have not always distinguished between using a well-known, manualized psychotherapy, providing psychoeducation and psychological support, or providing a therapy specifically to integrate the drug experience in psychedelic trials. Also, it is difficult to determine the role of the psychedelic agent as a stand-alone treatment, and the relative importance (if any) of the psychedelic experience for the desired therapeutic effect. In this perspective, we discuss the evolving landscape of psychedelic-based and ketamine-based treatments, highlighting different therapeutic models, their methodologies, and the need for clearer definitions and rigorous clinical trials. The document proposes three new definitions to improve clarity in evaluating the effects of these agents and the role of psychotherapies. We suggest language that will distinguish: (1) when the drug is used for its pharmacologic effects as a stand-alone treatment, without requiring the psychedelic experience or combined psychotherapy; (2) when the treatment requires the acute psychological effects of the drug to assist psychotherapy and (3) When ketamine or a psychedelic agent is used in combination with a structured, manualized psychotherapy that could be implemented even in the absence of these agents. We hope that this new terminology and definitions will help distinguish the various therapeutic roles of these agents (as stand-alone treatments or in combination with psychotherapies), and facilitate study designs, regulatory pathways, and more informed patient care. Plain Language Summary Title: Ketamine, Psychedelics, and Psychotherapy: Understanding treatment models to better inform practice
- Open Access
- 14 August 2025
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 35 (3) , S57-S89
Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review
Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the efficacy, safety, and future research priorities of these treatments for PTSD. A search strategy was implemented across 3 electronic databases. Peer-reviewed articles written in English that focused on interventional psychiatry treatments for adult patients with PTSD were included. The systematic review encompassed 94 studies, including 39 on transcranial magnetic stimulation (TMS), 8 on IV-KET, 3 on intranasal esketamine (IN-ESK), 4 on intravenous ketamine (IV-KET) assisted therapy (KET-AT), 1 on esketamine (ESK) assisted therapy (ESK-AT), and 14 on 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT). Randomized controlled trials demonstrated response rates of 12.5%-80% for TMS, 17%-67% for IV-KET, and 50%-87% for MDMA. Additional treatments reviewed included Electroconvulsive Therapy, transcranial direct current stimulation, and other pharmacological and neurostimulation treatments. Most treatments were well tolerated, with only mild, transient adverse effects. This review highlights the heterogeneity in efficacy, safety, and tolerability across neuromodulation and pharmacologic treatments for PTSD. Variability in response rates reflects differences in patient populations, protocols, and comorbidities. While repetitive TMS, IV-KET, ESK, KET-AT, and MDMA-AT show symptom improvement, sustained efficacy varies, underscoring the need for maintenance strategies. Although direct evidence on stage-specific approaches is limited, these methods, guided by neuroscience-based nomenclature, may improve therapeutic precision, especially in complex cases.
- 14 August 2025
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 35 (3) , S57-S89
Open AccessInterventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review
Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the efficacy, safety, and future research priorities of these treatments for PTSD. A search strategy was implemented across 3 electronic databases. Peer-reviewed articles written in English that focused on interventional psychiatry treatments for adult patients with PTSD were included. The systematic review encompassed 94 studies, including 39 on transcranial magnetic stimulation (TMS), 8 on IV-KET, 3 on intranasal esketamine (IN-ESK), 4 on intravenous ketamine (IV-KET) assisted therapy (KET-AT), 1 on esketamine (ESK) assisted therapy (ESK-AT), and 14 on 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT). Randomized controlled trials demonstrated response rates of 12.5%-80% for TMS, 17%-67% for IV-KET, and 50%-87% for MDMA. Additional treatments reviewed included Electroconvulsive Therapy, transcranial direct current stimulation, and other pharmacological and neurostimulation treatments. Most treatments were well tolerated, with only mild, transient adverse effects. This review highlights the heterogeneity in efficacy, safety, and tolerability across neuromodulation and pharmacologic treatments for PTSD. Variability in response rates reflects differences in patient populations, protocols, and comorbidities. While repetitive TMS, IV-KET, ESK, KET-AT, and MDMA-AT show symptom improvement, sustained efficacy varies, underscoring the need for maintenance strategies. Although direct evidence on stage-specific approaches is limited, these methods, guided by neuroscience-based nomenclature, may improve therapeutic precision, especially in complex cases.
- Open Access
- 12 August 2025
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 30 (1) , 1-39
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments
G protein-coupled receptors (GPCRs) are involved in many physiological and pathophysiological processes. Conventional pharmacological models categorize the typology of pharmacologic ligands as agonists or antagonists. Biased agonism is a relatively newer pharmacodynamic characteristic that has potential to optimize therapeutic efficacy while minimizing adverse effects in psychiatric and neurological treatments. We conducted a narrative literature review of articles obtained from PubMed, Embase, and MEDLINE from inception to April 2025, focusing on pharmacologic antagonism (i.e., competitive, noncompetitive, uncompetitive) and agonism (i.e., full, partial, inverse, superagonism, biased). Primary and secondary articles defining these concepts were included, provided they addressed pharmacologic (rather than chemical) antagonism and agonism. Distinct mechanisms of antagonism and agonism were identified, each contributing nuanced receptor modulation beyond the conventional models. Notably, biased agonism facilitates targeted intracellular signaling (e.g., G protein- versus β-arrestin–mediated). Use cases demonstrate relatively greater efficacy (e.g., incretin receptor agonist, tirzepatide) and improved safety (e.g., serotonergic psychedelics, opioids). Biased agonism provides a potential avenue for future drug development, with emerging preclinical evidence suggesting potential to differentially activate intracellular pathways and thereby improve efficacy and safety profiles of psychopharmacologic agents—pending clinical validation. Future research vistas should aim to rigorously assess the long-term outcomes of biased agonism, explicitly addressing individual variability in receptor signaling and therapeutic response.
- 12 August 2025
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 30 (1) , 1-39
Open AccessBiased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments
G protein-coupled receptors (GPCRs) are involved in many physiological and pathophysiological processes. Conventional pharmacological models categorize the typology of pharmacologic ligands as agonists or antagonists. Biased agonism is a relatively newer pharmacodynamic characteristic that has potential to optimize therapeutic efficacy while minimizing adverse effects in psychiatric and neurological treatments. We conducted a narrative literature review of articles obtained from PubMed, Embase, and MEDLINE from inception to April 2025, focusing on pharmacologic antagonism (i.e., competitive, noncompetitive, uncompetitive) and agonism (i.e., full, partial, inverse, superagonism, biased). Primary and secondary articles defining these concepts were included, provided they addressed pharmacologic (rather than chemical) antagonism and agonism. Distinct mechanisms of antagonism and agonism were identified, each contributing nuanced receptor modulation beyond the conventional models. Notably, biased agonism facilitates targeted intracellular signaling (e.g., G protein- versus β-arrestin–mediated). Use cases demonstrate relatively greater efficacy (e.g., incretin receptor agonist, tirzepatide) and improved safety (e.g., serotonergic psychedelics, opioids). Biased agonism provides a potential avenue for future drug development, with emerging preclinical evidence suggesting potential to differentially activate intracellular pathways and thereby improve efficacy and safety profiles of psychopharmacologic agents—pending clinical validation. Future research vistas should aim to rigorously assess the long-term outcomes of biased agonism, explicitly addressing individual variability in receptor signaling and therapeutic response.
- Open Access
- 11 August 2025
- Vol. 35 (Suppl 1) , S152-S167
Evolving Psychotherapeutic Approaches for PTSD: Beyond the Fear-Based Model.
Traditional trauma-focused psychotherapies (TFPs) were developed based on an anxiety disorder model of posttraumatic stress disorder (PTSD). However, PTSD is a more complex disorder with heterogeneous onset, presentation, trajectory, and treatment responsivity. As half of treated patients do not respond to first-line treatments, innovative therapies are emerging to improve outcomes. This narrative review of therapist-delivered psychotherapies for PTSD focuses on interventions not yet endorsed by clinical guidelines. A systematic search of MEDLINE and American Psychological Association PsycINFO was conducted for English-language human clinical studies, guidelines, and reviews related to PTSD psychotherapy through June 29, 2024. Data were thematically analyzed, focusing on how emerging interventions modify or diverge from current guideline-recommended treatments. The review identified 4 key themes for improving trauma therapy: (1) optimizing existing TFPs, (2) adapting psychotherapies used for other conditions, (3) reimagining exposure therapies, and (4) new therapeutic modalities. New exposure treatments include those capitalizing on memory reconsolidation science, combination with pharmacotherapies, neuromodulation, or virtual reality technologies, and mind-body and somatic psychotherapies. Moral injury, identity, and spirituality-focused therapies aim to resolve intense internal conflicts, guilt and shame, and issues of meaning and purpose. Finally, multi-modal treatments like 3MDR and psychedelic-assisted psychotherapies have multiple synergistic mechanisms. Ongoing research will be crucial to validating emerging approaches and optimizing their combined potential. A PTSD staging model may provide a structured framework for rigorous empirical evaluation and clinical implementation. Future research should prioritize randomized controlled trials with diverse patient populations and long-term follow-up to ensure their safety, efficacy, and scalability.
- 11 August 2025
- Vol. 35 (Suppl 1) , S152-S167
Open AccessEvolving Psychotherapeutic Approaches for PTSD: Beyond the Fear-Based Model.
Traditional trauma-focused psychotherapies (TFPs) were developed based on an anxiety disorder model of posttraumatic stress disorder (PTSD). However, PTSD is a more complex disorder with heterogeneous onset, presentation, trajectory, and treatment responsivity. As half of treated patients do not respond to first-line treatments, innovative therapies are emerging to improve outcomes. This narrative review of therapist-delivered psychotherapies for PTSD focuses on interventions not yet endorsed by clinical guidelines. A systematic search of MEDLINE and American Psychological Association PsycINFO was conducted for English-language human clinical studies, guidelines, and reviews related to PTSD psychotherapy through June 29, 2024. Data were thematically analyzed, focusing on how emerging interventions modify or diverge from current guideline-recommended treatments. The review identified 4 key themes for improving trauma therapy: (1) optimizing existing TFPs, (2) adapting psychotherapies used for other conditions, (3) reimagining exposure therapies, and (4) new therapeutic modalities. New exposure treatments include those capitalizing on memory reconsolidation science, combination with pharmacotherapies, neuromodulation, or virtual reality technologies, and mind-body and somatic psychotherapies. Moral injury, identity, and spirituality-focused therapies aim to resolve intense internal conflicts, guilt and shame, and issues of meaning and purpose. Finally, multi-modal treatments like 3MDR and psychedelic-assisted psychotherapies have multiple synergistic mechanisms. Ongoing research will be crucial to validating emerging approaches and optimizing their combined potential. A PTSD staging model may provide a structured framework for rigorous empirical evaluation and clinical implementation. Future research should prioritize randomized controlled trials with diverse patient populations and long-term follow-up to ensure their safety, efficacy, and scalability.
- Open Access
- 9 July 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (7) , e70661
Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
Background : Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have emerged as potential therapeutic options for psychiatric symptoms due to their effects on mood and behavior. However, their use has been primarily for metabolic diseases, and limited research has evaluated their psychiatric efficacy. This systematic review examined the impact of GLP‐1 RAs on psychiatric symptoms, categorizing studies based on whether psychiatric outcomes were primary or secondary. Methods : A comprehensive search through OVID databases from inception to November 2024 identified 26 studies ( n = 3020), with 5 studies evaluating psychiatric symptoms as primary outcomes (e.g., substance use disorders) and 21 studies assessing secondary outcomes across various conditions. Additionally, 10 registered clinical trials were identified. Results : Among the five studies targeting primary outcomes, exenatide and dulaglutide were investigated in cocaine use disorder, alcohol use disorder, and nicotine dependence. Exenatide 2 mg once‐weekly demonstrated reductions in cocaine craving in two cases over 6 weeks in a case series study. However, mixed results were reported across studies, including no significant changes in a separate case series ( n = 12, p = 0.46). Dulaglutide 1.5 mg weekly did not significantly affect smoking abstinence (RR = 0.87, p = 0.25) but reduced alcohol consumption by 29% in a secondary analysis. For studies assessing secondary outcomes, GLP‐1 RAs showed variable effects. In mood disorders, liraglutide 1.8 mg/day significantly improved depression and anhedonia. In Type 2 diabetes, semaglutide improved diabetes‐related quality of life (Cohen' and anxiety (Cohen's d = 0.48) compared to dulaglutide. Exenatide studies reported mixed results, with one randomized controlled trial (RCT) showing significant reductions in Beck's Depression Inventory (BDI) scores ( Δ = −5.2). A total of nine RCTs were included in this review and the risk of bias was assessed using the JBI Critical Appraisal Checklist for RCTs. All included RCTs met the majority of criteria, indicating moderate‐to‐high methodological quality. Of the included RCTs, three reported a statistically significant effect on the primary psychiatric outcome, whereas six reported no significant effect. Conclusion : GLP‐1 RAs showed mixed and inconclusive effects on psychiatric symptoms. Although some studies suggested potential benefits, others reported null findings. Given the variability across trials, further research is needed to clarify their therapeutic potential.
- 9 July 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (7) , e70661
Open AccessEfficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
Background : Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have emerged as potential therapeutic options for psychiatric symptoms due to their effects on mood and behavior. However, their use has been primarily for metabolic diseases, and limited research has evaluated their psychiatric efficacy. This systematic review examined the impact of GLP‐1 RAs on psychiatric symptoms, categorizing studies based on whether psychiatric outcomes were primary or secondary. Methods : A comprehensive search through OVID databases from inception to November 2024 identified 26 studies ( n = 3020), with 5 studies evaluating psychiatric symptoms as primary outcomes (e.g., substance use disorders) and 21 studies assessing secondary outcomes across various conditions. Additionally, 10 registered clinical trials were identified. Results : Among the five studies targeting primary outcomes, exenatide and dulaglutide were investigated in cocaine use disorder, alcohol use disorder, and nicotine dependence. Exenatide 2 mg once‐weekly demonstrated reductions in cocaine craving in two cases over 6 weeks in a case series study. However, mixed results were reported across studies, including no significant changes in a separate case series ( n = 12, p = 0.46). Dulaglutide 1.5 mg weekly did not significantly affect smoking abstinence (RR = 0.87, p = 0.25) but reduced alcohol consumption by 29% in a secondary analysis. For studies assessing secondary outcomes, GLP‐1 RAs showed variable effects. In mood disorders, liraglutide 1.8 mg/day significantly improved depression and anhedonia. In Type 2 diabetes, semaglutide improved diabetes‐related quality of life (Cohen' and anxiety (Cohen's d = 0.48) compared to dulaglutide. Exenatide studies reported mixed results, with one randomized controlled trial (RCT) showing significant reductions in Beck's Depression Inventory (BDI) scores ( Δ = −5.2). A total of nine RCTs were included in this review and the risk of bias was assessed using the JBI Critical Appraisal Checklist for RCTs. All included RCTs met the majority of criteria, indicating moderate‐to‐high methodological quality. Of the included RCTs, three reported a statistically significant effect on the primary psychiatric outcome, whereas six reported no significant effect. Conclusion : GLP‐1 RAs showed mixed and inconclusive effects on psychiatric symptoms. Although some studies suggested potential benefits, others reported null findings. Given the variability across trials, further research is needed to clarify their therapeutic potential.
- Open Access
- 19 June 2025
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee
Background: Intranasal (IN) esketamine has become an effective and well-tolerated therapeutic option for the management of treatment-resistant depression within major depressive disorder (MDD-TRD). Despite these promising benefits, given the prevalence of ketamine abuse, concerns remain over the addiction liability that may be associated with esketamine treatment. Objectives: The objective of this study is to assess the real-world abuse liability of this substance by tracking changes in likeability and cravings through an acute treatment course. Design: This is a secondary analysis of a previously published multicenter observational study. Methods: Likeability and craving for esketamine were assessed using the Likeability and Cravings Questionnaire (LCQ) in MDD-TRD patients receiving an acute course of IN esketamine treatment (eight dosing sessions). The data were analyzed using descriptive statistics, multivariate analysis of variance (MANOVA), and pre-post effect size (Cohen’s d ). Results: Twenty-three patients (52.2% female, 43.5 ± 11.9 years old) were assessed. Most patients reported a neutral liking and no cravings for esketamine after their first dosing session. These metrics did not increase significantly by treatment endpoint. MANOVA showed that neither age, sex, baseline depression scores, the presence of side effects, or the study site had a statistically significant impact on LCQ scores either alone or in combination. Conclusion: These results agree with the available literature, showing that an acute course of IN esketamine treatment was not associated with high levels of drug liking or cravings, and this did not increase through the course of eight treatments. Though larger studies are needed, esketamine does not appear to be associated with significant abuse liability when used in an acute course of treatment for patients with MDD-TRD. These are important results for this patient population and for clinical practice.
- 19 June 2025
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Open AccessAbuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee
Background: Intranasal (IN) esketamine has become an effective and well-tolerated therapeutic option for the management of treatment-resistant depression within major depressive disorder (MDD-TRD). Despite these promising benefits, given the prevalence of ketamine abuse, concerns remain over the addiction liability that may be associated with esketamine treatment. Objectives: The objective of this study is to assess the real-world abuse liability of this substance by tracking changes in likeability and cravings through an acute treatment course. Design: This is a secondary analysis of a previously published multicenter observational study. Methods: Likeability and craving for esketamine were assessed using the Likeability and Cravings Questionnaire (LCQ) in MDD-TRD patients receiving an acute course of IN esketamine treatment (eight dosing sessions). The data were analyzed using descriptive statistics, multivariate analysis of variance (MANOVA), and pre-post effect size (Cohen’s d ). Results: Twenty-three patients (52.2% female, 43.5 ± 11.9 years old) were assessed. Most patients reported a neutral liking and no cravings for esketamine after their first dosing session. These metrics did not increase significantly by treatment endpoint. MANOVA showed that neither age, sex, baseline depression scores, the presence of side effects, or the study site had a statistically significant impact on LCQ scores either alone or in combination. Conclusion: These results agree with the available literature, showing that an acute course of IN esketamine treatment was not associated with high levels of drug liking or cravings, and this did not increase through the course of eight treatments. Though larger studies are needed, esketamine does not appear to be associated with significant abuse liability when used in an acute course of treatment for patients with MDD-TRD. These are important results for this patient population and for clinical practice.
- Open Access
- 17 June 2025
- Published by Elsevier in Psychiatry Research Communications
- Vol. 5 (3)
A framework to assess risks for non-medical use of psychedelics: The liability for abuse of psychedelics questionnaire (LAPQ)
- 17 June 2025
- Published by Elsevier in Psychiatry Research Communications
- Vol. 5 (3)
Open AccessA framework to assess risks for non-medical use of psychedelics: The liability for abuse of psychedelics questionnaire (LAPQ)
- Open Access
- 26 May 2025
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 30 (1) , 1-19
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications
Major depressive disorder (MDD) is a chronic, highly prevalent, and debilitating mental disorder associated with significant illness and economic burden globally. Exposure to trauma (eg, physical, sexual, emotional abuse, and/or physical, and emotional neglect) is common among individuals with MDD. Persons with MDD and a history of trauma often exhibit an attenuated response to conventional serotonergic antidepressants compared to those with non-traumatized depression. Emerging evidence indicates that exposure to trauma is associated with increased inflammatory markers [eg, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)] as well as glutamatergic dysregulation in the central nervous system (CNS). It is hypothesized that individuals with MDD and a history of trauma may be conceptualized as a distinct bio-phenotype compared to non-traumatized depression. Furthermore, preliminary evidence positions select glutamatergic modulators as potential, novel, mechanistically-informed therapeutic strategies that may provide benefit to persons with elevated inflammation and glutamatergic dysregulation.
- 26 May 2025
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 30 (1) , 1-19
Open AccessShould glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications
Major depressive disorder (MDD) is a chronic, highly prevalent, and debilitating mental disorder associated with significant illness and economic burden globally. Exposure to trauma (eg, physical, sexual, emotional abuse, and/or physical, and emotional neglect) is common among individuals with MDD. Persons with MDD and a history of trauma often exhibit an attenuated response to conventional serotonergic antidepressants compared to those with non-traumatized depression. Emerging evidence indicates that exposure to trauma is associated with increased inflammatory markers [eg, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)] as well as glutamatergic dysregulation in the central nervous system (CNS). It is hypothesized that individuals with MDD and a history of trauma may be conceptualized as a distinct bio-phenotype compared to non-traumatized depression. Furthermore, preliminary evidence positions select glutamatergic modulators as potential, novel, mechanistically-informed therapeutic strategies that may provide benefit to persons with elevated inflammation and glutamatergic dysregulation.